Recon: Sanofi to Acquire Synthrox for $2.5B While Merck Picks up ArQule for $2.7B - Regulatory Focus

Recon: Sanofi to Acquire Synthrox for $2.5B While Merck Picks up ArQule for $2.7B  Regulatory Focus

Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more